A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test an experimental drug combination of two medications currently approved by the Food and Drug Administration (FDA) for migraine headache or other pain. These are called rizatriptan given with acetaminophen.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Diamond Headache Clinic
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Acetaminophen; Rizatriptan

Criteria

Inclusion Criteria:

• Subject is at least 18 years of age

• Subject has at least a 6 month history of migraine, with or without aura

• Subject can distinguish between migraine attacks and other types of headaches

• Subject of childbearing potential agrees to use adequate contraception

Exclusion Criteria:

• Subject typically has fewer than 1 or greater than 6 migraine attacks per month

• Subject typically has greater than 10 headache days per month

• Subject has evidence of ischemic heart disease

• Subject has uncontrolled high blood pressure

• Subject has a history, within 1 year, or current evidence of drug or alcohol abuse

*This list is not all inclusive*